SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: George Mc Geary who wrote (831)3/1/2000 11:05:00 PM
From: Ian@SI  Read Replies (1) of 1321
 
George,

You very well may get your wish.

QLT is expecting FDA approval early in 2Q2000. There are no major issues outstanding and no new issues have been raised.

We should also see a series of press releases between now and the end of April when ARVO is held in Fort Lauderdale. Prior to that the 2 year results (not the details) for the TAP trial should be issued in a press release.

Full enrollment has been achieved for all of the trials underway. Should see preliminary results (6 month checkpoint agreed to with FDA) for the Barrett's trial by 4Q.

Several others will yield results in 3Q2000:

Phase 2 Psoriasis study.
Phase 2 NonMelanoma Skin Cancer study
and the Rheumatoid Arthritis proof of concept.

And their third Photodynamic drug is being readied for trials this year.

All in all, looks like some exciting growth potential ahead for QLT.

Ian.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News